Pulmonary fibrosis associated with low-dose adjuvant methyl-CCNU.
Pulmonary fibrosis is a serious side effect of nitrosourea therapy, occurring most frequently in patients treated with BCNU. Pulmonary fibrosis developed in a 63 year-old male patient while being treated with adjuvant methyl-CCNU for rectal carcinoma. This toxicity is rare with methyl-CCNU, having only been reported once previously. The case of methyl-CCNU-induced pulmonary fibrosis reported here occurred at a much lower total dose than the first reported case (604 mg/m2 vs. 2,733 mg/m2). Details of the case history, including radiographic and pathologic findings, are presented.
Block
M
M
Regional Cancer Center, Lourdes Hospital, Binghamton, New York.
Lachowiez
R M
RM
Rios
C
C
Hirschl
S
S
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003131:Combined Modality Therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D009607:Nitrosourea Compounds / Q000009:adverse effects*; D011658:Pulmonary Fibrosis / Q000139:chemically induced*; D012004:Rectal Neoplasms / Q000188:drug therapy; D012673:Semustine / Q000008:administration & dosage / Q000009:adverse effects*
D009607:Nitrosourea Compounds; D012673:Semustine